Contact CFFC

Nov

Clinical Trial Alerts – November 2021

Cystic Fibrosis Foundation issued the following clinical trial alerts in November.

November 19, 2021

Study to evaluate Creon in adults with cystic fibrosis or chronic pancreatitis

Status: Enrolling

Description: This study will look at the symptoms of exocrine pancreatic insufficiency (EPI) in adults with cystic fibrosis or chronic pancreatitis treated with Creon with an alternate source of active drug. Creon is a drug approved to treat EPI. 

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: No FEV1 Limit

Number of Visits: 3

Length of Participation: 142 days

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT05069597

November 30, 2021

Study of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor, in children 2-5 years old with cystic fibrosis (Part B)

Status: Enrolling

Description: This study will look at the safety and effectiveness of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®), in children ages 2-5 years old with CF. These drugs are intended to help CFTR protein function closer to normal.

Age: 2 Years to 5 Years

Mutation: Two Copies F508del or One Copy F508del

Fev1% Predicted: No FEV1 Limit

Number of Visits: 9

Length of Participation: 32 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04537793


Comments are closed.